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Abstract
Background: The prevalence, and associated healthcare burden, of diabetes mellitus is increasing worldwide.
Mortality and morbidity are associated with diabetic complications in multiple organs and tissues, including the
eye, kidney and cardiovascular system, and new therapeutics to treat these complications are required urgently.
Triethylenetetramine (TETA) is one such experimental therapeutic that acts to chelate excess copper (II) in diabetic
tissues and reduce oxidative stress and cellular damage.
Methods: Here we have performed two independent metabolomic studies of serum to assess the suitability of the
streptozotocin (STZ)-induced rat model for studying diabetes and to define metabolite-related changes associated
with TETA treatment. Ultraperformance liquid chromatography-mass spectrometry studies of serum from non-
diabetic/untreated, non-diabetic/TETA-treated, STZ-induced diabetic/untreated and STZ-induced diabetic/TETA-
treated rats were performed followed by univariate and multivariate analysis of data.
Results: Multiple metabolic changes related to STZ-induced diabetes, some of which have been reported
previously in other animal and human studies, were observed, including changes in amino acid, fatty acid,
glycerophospholipid and bile acid metabolism. Correlation analysis suggested that treatment with TETA led to a
reversal of diabetes-associated changes in bile acid, fatty acid, steroid, sphingolipid and glycerophospholipid
metabolism and proteolysis.
Conclusions: Metabolomic studies have shown that the STZ-induced rat model of diabetes is an appropriate
model system to undertake research into diabetes and potential therapies as several metabolic changes observed
in humans and other animal models were also observed in this study. Metabolomics has also identified several
biological processes and metabolic pathways implicated in diabetic complications and reversed following
treatment with the experimental therapeutic TETA.
Background
Diabetes mellitus (DM) is a chronic debilitating condition
that is rapidly increasing in prevalence worldwide, as a
consequence of increases in obesity, changing patterns of
diet and physical activity, and ageing populations. The
World Health Organization estimated that 154 million
people in the world had DM at the beginning of the 21st
century [1]. In the USA the prevalence is estimated to
increase from 4.0 to 7.2% (or 29 million) between 2000
and 2050 [2].
DM is a metabolic disorder characterized by hypergly-
cemia. The hyperglycemia is caused as a consequence of
a deficiency in insulin in type 1 diabetes (T1D), and is a
feature of late type 2 diabetes (T2D) along with insulin
resistance. T2D is significantly more prevalent than
T1D. Molecular pathophysiological mechanisms that
precede hyperglycemia, or are observed with the clinical
symptoms of DM, include, among others, alterations in
lipid and amino acid metabolism [3-5], changes in
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hormone levels (including insulin [6] and adiponectin
[7]), increases in adipokine levels [8] and alterations in
copper metabolism [9]. The complications of DM
include cardiomyopathy, vasculopathy, neuropathy,
nephropathy and retinopathy, and are major causes of
morbidity and mortality. Current interventions in DM
are aimed at controlling blood glucose levels, dyslipide-
mia and blood pressure, but these have only modest
effects on reducing risk of progression to complications,
so better treatments are urgently required.
DM is a disease associated with multiple metabolic
abnormalities so the application of metabolomic techni-
ques to study it and potential interventions is appropriate
[10]. A recent review has highlighted the role of metabo-
lomics in the study of DM and cardiovascular diseases
[11]. Previous studies have reported alterations in bio-
fluid or tissue metabolic profiles in humans [3-5] and
experimental animal models of DM (obese Zucker rat
[12], db/db mouse [13], ddY-H mouse and streptozotocin
(STZ) rat [14,15]) applying metabolomics.
A number of animal models have been used to study
DM [16] and here we chose to apply the commonly used
STZ rat model. STZ is a toxin with the ability to induce
selective destruction of pancreatic beta cells resulting in
insulin deficiency and hyperglycemia [17]. In the STZ rat
model, the concentration of insulin decreases rapidly
after STZ-induced beta cell destruction and the blood
glucose levels increase to greater than 11 mmol/L. The
STZ rat model of diabetes has been widely investigated
since 1963 and is one of the most commonly used mod-
els of human disease. It is known to mimic many of the
acute and some of the chronic complications observed in
human diabetes. This model has the advantage of being
highly reproducible and the time lines for various com-
plications to develop are well recognized and reproduci-
ble. Given the established similarities of some of the
structural, functional and biochemical abnormalities to
human disease, it is considered an appropriate model to
assess mechanisms of diabetes and evaluate potential
therapies.
One potential treatment under investigation to treat dia-
betic complications (though not to reverse hyperglycemia)
is the copper (II)-selective chelator triethylenetatramine
(TETA) [18]. Recent research has described elevated
plasma and urine concentrations of copper in human and
experimental DM (including the STZ-diabetic rat model
[19]) and copper concentrations are highest in subjects
with diabetic complications such as retinopathy and
nephropathy. Retention of copper has been shown in the
kidney [19], liver [19] and heart [20] in DM and plays a
role in increased cellular oxidative stress through
enhanced production of reactive oxygen species (in parti-
cular the hydroxyl radical) through Haber-Weiss Fenton
reactions. Oral treatment with copper chelators has been
shown to reverse DM-induced changes and restore copper
homeostasis (reviewed in [18]). The copper (II)-selective
chelator TETA, which is used as a second line treatment
for Wilson’s disease, ameliorates cardiomyopathy [20,21]
and diabetes-induced nephropathy [22]. Furthermore, a
recently completed phase 2a clinical trial has shown
TETA to be well tolerated in DM and to improve hyper-
glycemia-induced left ventricular hypertrophy and diasto-
lic dysfunction [21]. TETA has also been demonstrated to
have anti-angiogenic properties and its potential use in
cancer chemotherapy is under investigation [23].
The two primary objectives of the research described
were to (i) assess the metabolic changes in the STZ-
induced rat model of DM and compare these changes to
metabolic changes observed in published research in rela-
tion to other animal models of DM and (ii) to investigate
the metabolic response to TETA treatment in the STZ-
induced rat model of DM. Serum was chosen as an appro-
priate biofluid to integrate the diabetes-induced changes
that occur in multiple tissues. The investigation of the
serum metabolome was chosen as DM is defined as a
metabolic disorder and changes in metabolism are
expected. The application of metabolomics to study the
effect of TETA treatment on the reversal of diabetic com-
plications is also appropriate; the mode of action of TETA
is to chelate copper and reduce oxidative stress in cells
and tissues. Markers of oxidative stress (including oxidized
lipids) are expected to be observed in the serum metabo-
lome. This study had the potential to identify metabolic
biomarkers to apply in other studies - for example, the
monitoring of drug safety and efficacy in clinical trials.
Two independent but similar biological studies were per-
formed at different times, each assessing metabolic differ-
ences in four groups: (i) non-diabetic/untreated rats, (ii)
non-diabetic/TETA-treated rats, (iii) STZ-induced
diabetic/untreated rats and (iv) STZ-induced diabetic/
TETA-treated rats. Ultraperformance liquid chromatogra-
phy-mass spectrometry (UPLC-MS) and univariate/multi-
variate data analysis methods were applied to determine
differences in the serum metabolomes associated with
STZ-induced DM and TETA treatment.
Results
Treatment of the rats with intraperitoneal STZ resulted in
elevated plasma glucose levels consistent with diabetes
(>30 mmol/L), whereas non-treated rats without STZ
injection had normal glucose levels (<7 mmol/L) in each
of the two studies. Time-independent replicate studies
were performed with metabolomic analyses undertaken in
November 2009 (study 1) and May 2010 (study 2). Half
the rats in the non-diabetic and diabetic groups were trea-
ted with TETA, that is, there were four groups in total. In
studies 1 and 2 the numbers of rats, which were present in
each of the four classes at time of sacrifice, were as follows:
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non-diabetic/untreated (study 1, n = 9; study 2, n = 10),
nondiabetic/TETA-treated (study 1, n = 6; study 2, n =
10), STZ-induced diabetic/untreated (study 1, n = 9; study
2, n = 10) and STZ-induced diabetic/TETA-treated (study,
1 n = 6; study 2, n = 10). Following quality assurance pro-
cedures, 4,826 and 7,425 metabolic features were detected
in positive ion mode in studies 1 and 2, respectively, and
1,369 and 3,469 metabolic features in negative ion mode
in studies 1 and 2, respectively. These metabolic features
were taken forward for further data analysis. Of these
metabolic features, 51.9% and 40.3% of metabolic features
were putatively identified in the two studies, respectively,
following the process of metabolite identification. This
highlights that not all metabolites are identified in untar-
geted metabolic studies.
Principal components analysis (PCA) was performed
applying all detected metabolic features to assess the
variability in the data and determine whether outliers
were present. Figure 1a,b shows the PCA score plots
(PC1 versus PC2) for positive (Figure 1a) and negative
(Figure 1b) ion mode data acquired in study 1. One
potential outlier was identified in positive ion mode only,
most probably a result of a poor injection as the total
peak area for all metabolites was lower than for other
samples, and was removed prior to univariate data analy-
sis. The quality control (QC) samples are tightly clustered
in comparison to the rat serum samples, showing that the
reproducibility of data acquired in a single UPLC-MS
experiment is high. Distinct and clear separation in PC1
indicates a large difference in the serum metabolome
related to the differences between STZ-induced diabetic
rats and non-diabetic rats, independent of whether rats
were treated or untreated with TETA. No clear separa-
tion was observed when comparing STZ-induced diabetic
rats that were TETA treated or untreated and no clear
separation was observed when comparing non-diabetic
rats that were TETA treated or untreated. Similar obser-
vations were observed in study 2.
Univariate statistical analyses were performed to iden-
tify metabolic features whose relative concentrations
were statistically different (P < 0.05) between different
pairwise combinations of the four study groups. A single
metabolite can be detected as different metabolic fea-
tures, each with the same retention time but a different
m/z value caused by the detection of different ionic spe-
cies of the same metabolite (for example, protonated and
sodiated ions). Also, a single metabolic feature can relate
to multiple stereoisomers. Therefore, multiple metabolic
features can correspond to a single metabolite or stereoi-
somer. The number of statistically significant (P < 0.05)
metabolic features for each comparison and animal study
and the number of metabolic features observed as statis-
tically significant in both studies are shown in Table 1.
When comparing the STZ-induced diabetic/untreated
and non-diabetic/untreated rats, a large number of differ-
ences in the serum metabolome were observed. A small
number of changes were observed when comparing STZ-
induced diabetic/TETA-treated against STZ-induced dia-
betic/untreated rats and non-diabetic/TETA-treated
against non-diabetic/untreated rats. A range of metabolic
features were observed to be statistically different in only
one of the two studies and a subset of metabolic features
was reproducibly observed in both independent studies;
49.0 to 97.9% of statistically significant features defined
in one study were not reported as statistically significant
in the other study and can therefore be defined as false
positives. This highlights the potential for false observa-
tions in these types of discovery investigations and an
appropriate manner in which to reduce the probability of
false positives through two separate discovery studies. In
summary, as shown for the PCA analysis, the major
changes as defined following univariate analysis are
related to diabetic status and fewer changes were
observed when comparing TETA-treated and untreated
rats.
Table 2 describes the 148 metabolic features whose
concentration changes were statistically significant (P <
0.05) (i) when comparing STZ-induced diabetic/
untreated versus non-diabetic/untreated rats, (ii) in both
independent studies and (iii) with the same direction of
relative change (up-regulation or down-regulation) in
both independent studies. This provides further confi-
dence that the metabolites defined as ‘biologically inter-
esting’ are relevant and deserve further investigation.
Specific metabolite classes that are over-represented in
the results include amino acids and related metabolites
(10 metabolites), bile acids (5 metabolites), dipeptides
(2 metabolites), long- and short chain fatty acids and
related metabolites (23 metabolites), glycerophospholi-
pids (41 metabolites), nucleosides, nucleotides and purine
metabolites (6 metabolites), sphingolipids (4 metabolites)
and vitamin D metabolites (3 metabolites).
The statistical analysis showed a limited number of
metabolic features whose change in concentration was
statistically significant when comparing STZ-induced dia-
betic/TETA-treated versus STZ-induced diabetic/
untreated rats. These are shown in Table 3. To further
assess changes in the complex interactions of metabolites
in metabolic networks, we performed pairwise correlation
analysis for three groups in study 2: (i) non-diabetic/
untreated, (ii) STZ-induced diabetic/untreated and (iii)
STZ-induced diabetic/TETA-treated. This was per-
formed to assess potential complex mechanistic actions
of TETA not revealed by univariate analysis. Study 2 was
selected as a higher number of rats per group survived to
12 weeks compared to study 1. There were 3.4 million
pairwise comparisons. Data were further filtered to detail
metabolic features that showed (a) a high positive or
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negative correlation for non-diabetic/untreated rats and
for STZ-induced diabetic/TETA-treated rats (arbitrary
chosen as > +0.5 or < -0.5) and (b) a change in the corre-
lation coefficient of >0.5 when comparing non-diabetic/
untreated rats with STZ-induced diabetic/untreated rats.
Pairwise correlations between different metabolic
features of the same metabolite were removed from the
dataset and metabolites showing changes in ten or more
pairwise correlations with other metabolites were passed
forward for biological interpretation. The filtering work-
flow was chosen to investigate the complex metabolic
network in operation and to define metabolites that are
Figure 1 Principal components analysis (PCA) score plots. (a,b) Data acquired in positive (a) and negative (b) ion modes in independent
study 1. The letter ‘A’ represents non-diabetic/triethylenetetramine-treated, ‘B’ non-diabetic/untreated, ‘C’ STZ-induced diabetic/
triethylenetetramine-treated, ‘D’ STZ-induced diabetic/TETA-untreated and ‘X’ the QC samples.
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highly correlated on a pairwise comparison to other
metabolites in non-diabetic/untreated rats and that lose a
high correlation in STZ-induced diabetic/untreated rats
but in which the high correlation returns in STZ-induced
diabetic/TETA-treated rats. These features highlight
positive changes produced by TETA treatment in dia-
betic rats and are shown in Additional file 1. Specific
classes of metabolites were over-represented in the
results, including bile acids (6 metabolites), fatty acids
(19 metabolites), glycerophospholipids (37 metabolites),
sterol-based metabolites (7 metabolites), vitamin D meta-
bolites (11 metabolites) and sphingolipids (6 metabolites).
Multiply-charged species (338 metabolic features) were
also over-represented in the results.
Discussion
Diabetes is a multi-factorial metabolic disease. To study
metabolic alterations in an experimental, STZ-induced
animal model of DM, we applied UPLC-MS based meta-
bolic profiling. Investigation of serum from animals 12
weeks after induction of the diabetes-like insult with com-
parison to non-diabetic controls, both in the presence and
absence of oral treatment with TETA, were performed.
Identification of changes in relative metabolite concentra-
tions revealed changes of specific metabolic pathways or
areas of metabolism in response to DM and treatment
with TETA.
Changes in the serum metabolome related to molecular
pathophysiological mechanisms of diabetes
In addition to the expected hyperglycemia, changes in the
serum concentrations of amino acids and related metabo-
lites, bile acids, dipeptides, short and long-chain fatty
acids and related metabolites, glycerophospholipids,
nucleosides/nucleotides/purine metabolites, organic
acids, sphingolipids and vitamin D metabolites were
observed. These metabolic changes could be a result of
mechanisms related to DM and associated tissue-specific
complications but also unexpected secondary actions of
treatment with STZ. However, the findings of our study
are compatible with known altered mechanisms in DM,
making it reasonable to believe that these changes are
related to the diabetic state. A selection of biologically
important alterations related to potential tissue-specific
changes and observed in human and other animal models
of DM will be discussed below. These previously
observed changes highlight the applicability of the STZ-
induced rat model to the study of metabolic perturba-
tions in DM.
Changes in branched-chain amino acid metabolism
related to altered catabolism have been reported pre-
viously in the pre-diabetic state in humans [3,5] and in
animal models [24]. In our study, increased concentrations
of leucine and/or isoleucine as well as isovalerylalanine
and/or isovalerylsarcosine (applied as a biomarker of iso-
valeric acidemia) in the diabetic rats indicate disturbances
to branched-chain amino acid metabolism. Connor and
colleagues [13] observed changes in branched-chain
amino acid and isovaleryl-amino acids in the urine of dia-
betic db/db mice. Leucine has effects on different pro-
cesses that can relate to insulin resistance and glucose
intolerance and include hepatic gluconeogenesis, pancrea-
tic beta cell function, intracellular mammalian target of
rapamycin (mTOR) signaling, and the generation of inter-
mediates that are potentially toxic to mitochondrial func-
tion [25]. One potential intervention being investigated for
DM is metabolic Roux-en-Y gastric bypass, which surpris-
ingly appears to reverse symptoms and complications in
morbidly obese diabetic patients [26]. The current intri-
guing question as to why gastric bypass surgery reverses
DM symptoms has implicated leucine as playing an
important role [25].
Arginine, proline and oxoproline, which all decreased
in concentration in the diabetic rats, are metabolically
closely connected and are downstream products of the
urea cycle. Creatinine is also present at lower concentra-
tions in this study. Alterations to urea cycle intermediates
in humans [27] and animals [28,13] and urea cycle
enzymes in STZ-induced diabetic rats have been reported
previously [29]. These changes most likely reflect dia-
betes-mediated hepatic dysfunction, although altered
creatinine metabolism in tissues such as the heart have
Table 1 Summary of the number of metabolic features that show statistically significant differences (P < 0.05) in each








Non-diabetic/TETA-treated rats versus non-diabetic/untreated rats 234 211 5
Non-diabetic/TETA-treated rats versus STZ-induced diabetic/TETA-treated rats 1,129 3,077 576
Non-diabetic/TETA-treated rats versus STZ-induced diabetic/untreated rats 1,310 2,943 623
Non-diabetic/untreated rats versus STZ-induced diabetic/TETA-treated rats 1,480 3,308 768
Non-diabetic/untreated rats versus STZ-induced diabetic/untreated rats 1,677 2,982 791
STZ-induced diabetic/TETA-treated rats versus STZ-induced diabetic/untreated rats 145 406 12
STZ, streptozotocin; TETA, triethylenetetramine.
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Table 2 Metabolites shown as statistically significant (P < 0.05) when comparing non-diabetic/untreated and










Amino acids and related metabolites
Isovalerylalanine AND/OR isovalerylsarcosine 0.00049 8.20 0.00016 2.85
5-Methoxytryptophan 0.00113 7.74 0.00038 2.13
N-[O-Phosphono-pyridoxyl]-isoleucine 0.00150 2.46 0.00115 3.30
Isoleucine AND/OR leucine AND/OR norleucine AND/OR N-methylvaline 0.00035 2.39 0.00067 1.51
Arginine 0.02434 0.67 0.00016 0.54
Beta-cyclohexyl-alanine 0.00411 0.66 0.00320 0.81
Proline 0.00708 0.65 0.00320 0.77
2-Methylserine AND/OR homoserine AND/OR allothreonine 0.00932 0.51 0.00024 0.41
Oxoproline 0.03347 0.45 0.00038 0.50
Tryptophan 0.00035 0.42 0.00016 0.44
Bile acids
24-Nor-5beta-cholane-3alpha,7alpha,12alpha,22,23-pentol 0.00127 2.84 0.00016 2.10
24-Nor-5beta-chol-22-ene-3alpha,7alpha,12alpha-triol AND/OR (22R)-3alpha,7alpha,22-
Trihydroxy-5beta-cholan-24-oic acid
0.02092 2.14 0.04937 1.71
(22E)-3alpha,6beta,7beta-trihydroxy-5beta-chol-22-en-24-oic acid AND/OR 3,7-
dihydroxy-12-oxocholanoic acid
0.03877 1.94 0.03376 3.09
(22R)-3alpha,7alpha,22-trihydroxy-5beta-cholan-24-oic acid 0.03051 1.66 0.02334 1.92
(22E)-12alpha-hydroxy-3-oxochola-1,4,22-trien-24-oic acid AND/OR 12alpha-hydroxy-3-
oxochola-1,4,6-trien-24-oic acid
0.00067 0.85 0.00150 0.88
Dipeptides
Gamma-glutamyl-L-isoleucine AND/OR gamma-glutamyl-L-leucine 0.00035 3.79 0.00016 1.79
(5-L-Glutamyl)-L-glutamine 0.00035 0.36 0.00016 0.58
Fatty acids and related metabolites
Methyl-hexadecanedioic acid AND/OR heptadecanedioic acid AND/OR 9,10-
dihydroxy-13-hydroperoxy-11-octadecenoic acid
0.00172 3.41 0.00088 2.05
Dodecenedioic acid AND/OR 9,12-dioxo-dodecanoic acid 0.00093 2.26 0.00067 1.50
Octadecatrienoic acid 0.00708 1.90 0.00250 2.50
Hydroperoxyoctadecadienoic acid 0.02434 1.46 0.01261 1.96
Heptadecenoic acid 0.04694 1.26 0.03429 1.69
Hexadecenoic acid AND/OR methyl-pentadecenoic acid AND/OR dimethyl-
tetradecenoic acid
0.02434 0.63 0.00407 0.22
Hydroxydecadienedienoic acid 0.04600 0.56 0.04125 0.75
Hydroxydecanoic acid 0.00150 0.49 0.00051 0.46
Lysophospholipids
LysoPE(18:0) 0.03051 1.38 0.04937 1.20
LysoPE(18:2) 0.00708 1.33 0.00016 2.44
LysoPC(18:2) 0.03798 1.17 0.00029 1.26
LysoPC(18:1) 0.01185 0.70 0.02014 0.67
LysoPC(20:4) 0.01255 0.70 0.00021 0.60
LysoPC(16:1) 0.02434 0.65 0.00051 0.21
LysoPC(14:0) 0.00093 0.57 0.00250 0.29
LysoPC(20:1) 0.00541 0.48 0.01261 0.61
LysoPC(22:6) 0.00172 0.46 0.00320 0.46
LysoPC(dm16:0) 0.00035 0.43 0.00088 0.56
LysoPC(O-16:2) 0.02092 0.32 0.01255 0.22
LysoPC(22:5) 0.00146 0.30 0.00021 0.27
Nucleosides, purine and pyrimidine metabolites
1,7-Dimethylxanthine AND/OR theobromine AND/OR theophylline 0.00035 3.40 0.00016 2.87
Thionicotinamide-adenine-dinucleotide 0.00035 2.68 0.00021 1.64
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Table 2 Metabolites shown as statistically significant (P < 0.05) when comparing non-diabetic/untreated and strepto-
zotocin-induced diabetic/untreated rats in both independent studies (Continued)
5-Methyl-2’-deoxycytidine 0.01255 2.54 0.00016 2.10
Hydroxyadenine AND/OR guanine 0.00049 0.81 0.00021 0.77
Cytosine 0.00049 0.73 0.00021 0.59
Deoxycytidine 0.03389 0.48 0.00016 0.32
Phospholipids
PC(36:2) 0.00035 2.95 0.00016 1.76
PE-NMe2(32:0) AND/OR PC(34:1) 0.00049 2.45 0.00115 1.23
PE(36:2) 0.00172 2.28 0.00016 2.47
PE(38:3) 0.00035 2.05 0.00051 1.44
PC(2:0/O-18:0) AND/OR PC(O-16:0/4:0) 0.00310 1.95 0.00250 1.42
PC(34:2) 0.00172 1.91 0.00016 1.38
PC(36:2) 0.00172 1.88 0.00016 1.51
PC(20:2/dm18:1) AND/OR PC(20:3/dm18:0) AND/OR PC(O-16:0/22:4) AND/OR PC(O-
18:0/20:4)
0.04550 1.72 0.00082 1.37
PE(38:2) 0.00067 1.59 0.00016 2.26
PC(34:3) 0.00232 1.54 0.00024 2.30
PC(36:4) 0.01185 1.52 0.00194 1.18
PC(6:0/O-16:0) AND/OR PC(O-12:0/10:0) AND/OR PC(O-18:0/4:0) AND/OR PC(O-20:0/
2:0)
0.00328 1.52 0.00220 1.62
PC(40:5) 0.00172 1.49 0.00194 1.13
PC(38:5) 0.00932 1.42 0.02837 1.06
PC(40:8) 0.03389 1.26 0.00465 1.31
PC(18:2/dm18:1) AND/OR PC(18:3/dm18:0) AND/OR PC(20:3/dm16:0) AND/OR PC(O-
16:0/20:4)
0.04236 1.19 0.01789 1.15
PC(32:1) 0.04694 0.84 0.00016 0.17
PC(36:0) 0.00708 0.70 0.02837 0.90
PC(16:0/O-16:0) AND/OR PC(O-14:0/18:0) 0.02689 0.69 0.00021 0.60
PC(O-8:0/O-8:0) 0.00093 0.62 0.00150 0.63
PC(44:9) 0.03347 0.61 0.00024 0.60
PC(42:7) 0.03389 0.55 0.00016 0.71
PC(18:1/dm18:1) AND/OR PC(18:2/dm18:0) AND/OR PC(20:2/dm16:0) AND/OR PC(O-
16:0/20:3) AND/OR PC(20:4/dm18:1)
0.00415 0.53 0.00194 0.63
PC(18:0/O-16:0) AND/OR PC(O-18:0/16:0) AND/OR PC(38:4) 0.01928 0.53 0.04937 0.86
PC(34:4) 0.00218 0.47 0.00024 0.31
PC(38:2) 0.00172 0.43 0.00051 0.60
PC(18:0/dm18:1) AND/OR PC(18:1/dm18:0) AND/OR PC(18:2/O-18:0) AND/OR PC(20:1/
dm16:0) AND/OR PC(P-18:0/18:1) AND/OR PC(20:3/dm18:1)
0.00232 0.32 0.00407 0.76
Short chain fatty acids and organic acids
Azelaic acid 0.00232 5.22 0.00051 1.68
Oxopentanoic acid AND/OR methyl-oxobutanoic acid 0.00035 4.95 0.00088 1.78
Hydroxybutanoic acid AND/OR methyl-hydroxybutanoic acid 0.01255 4.64 0.00016 3.13
2-Ethylhydracrylic acid AND/OR hydroxy-methylbutyric acid 0.00035 4.18 0.00016 2.42
Methylacetoacetic acid 0.00035 4.14 0.00150 1.40
3-Butenoic acid 0.00035 3.79 0.00016 2.66
2-Methylglutaconic acid AND/OR 2,3-dimethylmaleic acid AND/OR 2-
methyleneglutaric acid AND/OR 3-hexenedioic acid
0.00035 3.61 0.00194 1.49
Hydroxyacetone AND/OR propanoic acid AND/OR dihydroxybutyric acid AND/OR 4-
deoxyerythronic acid
0.00086 2.66 0.00016 1.51
Hydroxyhexanoic acid AND/OR 2-ethyl-2-hydroxybutyric acid 0.00093 2.51 0.00016 2.13
Glyceric acid 0.01417 2.01 0.00024 3.33
Isonicotinic acid AND/OR nicotinic acid AND/OR picolinic acid 0.01185 0.69 0.00650 0.86
Hydroxybenzoic acid AND/OR salicylic acid 0.02689 0.57 0.04125 0.74
Indolepyruvic acid 0.00150 0.56 0.00061 0.55
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Table 2 Metabolites shown as statistically significant (P < 0.05) when comparing non-diabetic/untreated and strepto-
zotocin-induced diabetic/untreated rats in both independent studies (Continued)
Methylindolepyruvic acid 0.03347 0.49 0.00220 0.51
Lactic acid 0.00415 0.34 0.00016 0.56
Sphingomyelines
SM(d18:1/18:1) 0.00541 1.73 0.00138 1.42
SM(d18:1/22:1) 0.00919 0.75 0.00815 0.67
SM(d18:1/14:0) 0.01517 0.60 0.00128 0.28
SM(d18:1/22:0) 0.00049 0.53 0.00021 0.47
Vitamin D metabolites
1Alpha,25-dihydroxy-19-nor-22-oxavitamin D3 AND/OR 26,27-dinor-
3alpha,6alpha,12alpha-trihydroxy-5beta-cholestan-24-one AND/OR linoleyl carnitine
0.00035 2.65 0.00038 3.36
11Alpha-hemiglutaryloxy-1,25-dihydroxyvitamin D3 0.02086 1.39 0.03429 1.30
(22E)-(24R)-1Alpha,24,25-trihydroxy-22,23-didehydrovitamin D3 0.01517 0.44 0.00021 0.29
Other metabolites
2,5,7,8-Tetramethyl-2-(2’-carboxyethyl)-6-hydroxychroman -glucuronide 0.03671 6.60 0.01123 5.60
C12 SUGAR 0.00035 5.59 0.00016 5.52
Harman 0.00035 5.00 0.00016 3.77
1-O-Coumaroyl-beta-D-glucose AND/OR 4-O-beta-D-glucosyl-4-hydroxycinnamate
AND/OR cis-beta-D-glucosyl-2-hydroxycinnamate AND/OR coumarinic acid-beta-D-
glucoside AND/OR trans-beta-D-glucosyl-2-hydroxycinnamic acid
0.00035 3.97 0.00029 3.36
Pteridine 0.00053 3.75 0.00051 2.28
1-(4’-Hydroxyphenyl)ethanol AND/OR 3-methoxybenzyl alcohol AND/OR 4-
hydroxyphenylethanol
0.00124 3.59 0.00016 1.86
C6 SUGAR 0.00035 3.36 0.00016 3.35
N-Formylpiperidine AND/OR 2-methylbutyrylglycine AND/OR 3-dehydrocarnitine 0.00127 3.09 0.00016 1.88
Leucine phosphonic acid AND/OR norleucine phosphonate AND/OR N-trimethyl-2-
aminoethylphosphonate
0.00146 2.72 0.00341 1.96
2-Amino-2-methylbutanoate AND/OR amino-pentanoic acid AND/OR 4-
methylaminobutyrate AND/OR betaine AND/OR isovaline AND/OR norvaline
0.00035 2.64 0.00029 1.60
Sebacic acid AND/OR 1,8-diaminooctane AND/OR 2-amyl 3-butenoic acid AND/OR
nonenoic acid AND/OR 4-hydroxynonenal AND/OR 6-methyl-5-octenoic acid
0.00919 2.51 0.00407 1.63
4-Hydroxyphenylacetylglutamic acid 0.00035 2.50 0.00016 3.35
Riboflavin 0.01742 2.21 0.00629 3.51
Neuromedin B (1-3) 0.00049 2.10 0.00088 1.95
12-Hydroxyjasmonic acid 12-O-beta-D-glucoside 0.04123 2.01 0.00239 5.74
N-(2-hydroxy-2S-methyl-ethyl)-16,16-dimethyl-5Z,8Z,11Z,14Z-docosatetraenoyl amine
AND/OR N-(2-methoxy-ethyl)-16,16-dimethyl-5Z,8Z,11Z,14Z-docosatetraenoyl amine
0.00179 1.80 0.00114 1.63
4-Hydroxyphenylacetonitrile AND/OR hydroxyindole AND/OR 2,5,6-trihydroxy-5,6-
dihydroquinoline AND/OR 3-succinoylpyridine AND/OR adrenochrome AND/OR
hippuric acid
0.00067 1.80 0.00320 1.48
4-Hydroxy-2-quinolinecarboxylic acid AND/OR indole-3-glyoxylic acid AND/OR
kynurenic acid
0.00937 1.78 0.01789 1.54
2,6-Dimethoxyphenol AND/OR 4-hydroxy-3-methoxy-benzenemethanol AND/OR
hydroxytyrosol
0.00950 1.69 0.03389 2.44
Urea 0.00067 1.68 0.00115 1.44
Dolichyl phosphate AND/OR 1,25-dihydroxy-2-nor-1,2-secovitamin D3 AND/OR
1alpha,25-dihydroxy-19-norvitamin D3
0.04486 1.66 0.04331 1.82
2,5,6-Trihydroxy-5,6-dihydroquinoline AND/OR 3-succinoylpyridine AND/OR
adrenochrome AND/OR hippurate
0.03051 1.64 0.00194 1.55
Bacteriohopane-32,33,34,35-tetrol 0.03075 1.59 0.00705 1.92
Acetylcarnitine 0.02789 1.56 0.00038 1.90
Palmitoyl glucuronide 0.02689 1.56 0.00016 1.49
2-Phenylethanol glucuronide 0.01928 1.46 0.00051 1.88
Methylnitrosourea 0.00127 1.45 0.00038 1.98
DG(36:4) 0.02689 1.34 0.00115 2.65
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been reported [28]. Proline has previously been shown in
animal models of DM to attenuate the SLC6A20 kidney
transporter [30]. Arginine supplementation has been
shown to increase brown fat mass and reduce white
adipose tissue in Zucker diabetic fatty rats (T2D) and
diet-induced obese rats through the enhancement of the
proliferation, differentiation, and function of brown adi-
pocytes [31]. In addition, both skeletal muscle mass and
whole body insulin sensitivity were enhanced in response
to arginine supplementation via mechanisms involving
increases in muscle mTOR and nitric oxide signaling
[32]. Therefore, the decreased concentrations of arginine
(as was observed in this study) are potentially detrimental
to normal function.
Other amino acid-related changes included an elevation
of 5-methoxytryptophan and a decrease in tryptophan
concentrations in diabetic animals; these changes have
been found previously in the retina [33]. So the increase in
5-methoxytryptophan we observed in serum could have
potential as a biomarker for retinal damage in diabetic
retinopathy, though further validation studies are required
to assess this potential application. Diabetic animals in this
study showed electroretinographic changes associated with
diabetes and increased retinal vascular permeability.
Creatine is decreased in this study and this has been
observed previously in animal models of DM, but in urine
and cardiac tissue. The decrease in cardiac tissue may be
related to increased demands of creatine/phosphocreatine
Table 2 Metabolites shown as statistically significant (P < 0.05) when comparing non-diabetic/untreated and strepto-
zotocin-induced diabetic/untreated rats in both independent studies (Continued)
1-(9Z,1Z-octadecadienoyl)-2-(10Z,13Z,16Z,19Z-docosatetraenoyl)-3-O-[hydroxymethyl-
N,N,N-trimethyl-beta-alanine]-glycerol
0.00310 1.30 0.00016 1.09
(22alpha)-Hydroxy-cholestanol AND/OR 3alpha,7alpha-dihydroxy-5beta-cholestane
AND/OR 5beta-cholestane-3alpha,12alpha-diol
0.03051 1.28 0.01261 1.33
3-Amino-3-(4-hydroxyphenyl)propanoic acid AND/OR 3-hydroxyphenylalanine AND/
OR threo-phenylserine AND/OR tyrosine
0.04694 0.84 0.00021 0.66
5-Hydroxy-2-polyprenylphenol AND/OR geranylhydroquinone 0.00919 0.80 0.00937 0.71
Glycinamide AND/OR N-acetyldiamine AND/OR N-methylurea AND/OR N-
nitrosodimethylamine
0.00067 0.79 0.00250 0.94
Cervonyl carnitine 0.00250 0.63 0.00115 0.54
Betaine citrate 0.00932 0.61 0.01123 0.61
Beta-cyclohexyl-alanine 0.00708 0.58 0.00250 0.81
3-Ureidoisobutyric acid AND/OR alanylglycine 0.00035 0.53 0.00016 0.45
Propenoate AND/OR alanine AND/OR beta-alanine AND/OR sarcosine 0.04694 0.52 0.00150 0.80
Creatinine 0.00035 0.48 0.00016 0.59
N-(3-Phenyl-2-sulfanylpropanoyl)phenylalanylalanine 0.00067 0.48 0.00016 0.56
Creatine 0.03798 0.45 0.00016 0.48
N1-Methyl-2-pyridone-5-carboxamide 0.00270 0.43 0.00109 0.47
All trans decaprenyl diphosphate 0.03389 0.42 0.00114 0.40
2-Methyl-5-hydroxytryptamine AND/OR 5-methoxytryptamine AND/OR cytisine AND/
OR N-methylserotonin
0.01255 0.39 0.00021 0.58
Dehydroisocoproporphyrinogen 0.00035 0.36 0.00220 0.23
5-Amino-5-deoxy-cellobiono-1,5-Lactam;6-(alpha-D-glucosaminyl)-1D-myo-inositol;6-
(alpha-D-glucosaminyl)-1D-myo-inositol
0.04331 0.31 0.00815 0.71
7,8,7’,8’-Tetradehydroastaxanthin 0.00035 0.23 0.00029 0.57
The metabolites are separated into functional classes and arranged in order of fold change of metabolite in study 1. Where multiple metabolic features were
reported for a single metabolite the feature with the P-value nearest 1 in study 1 is reported. For multiple metabolite identifications for a single metabolic
feature, each unique metabolite is separated by AND/OR. The total carbon number and the number of double bonds are indicated for lysophospholipids,
phospholipids and sphingomyelins. DG, diacylglycerol; dm, demethyl; PC, glycerophosphatidylcholine; PE, glycerophosphatidylethanolamine; PE-NMe,
monomethylphosphatidylethanolamine; SM, sphingomyelin.
Table 3 Metabolite shown as statistically significant (P < 0.05) when comparing streptozotocin-induced diabetic/










Hydroxybutanoic acid AND/OR methyl-
hydroxybutanoic acid
0.00898 1.25 0.00898 1.78
For multiple metabolite identifications for a single metabolic feature, each unique metabolite is separated by AND/OR.
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for energy production through rapid re-synthesis of ATP
from ADP in muscle and tissue with high energy demands
(for example, cardiac tissue).
Bile acids have an important role to play in regulation of
lipid, glucose and energy metabolism through the farne-
soid × receptor and the facilitation of postprandial nutri-
ent absorption by the gut [34]. Our study shows
similarities to previous studies highlighting an increased
bile acid pool in STZ-induced diabetic rats and other ani-
mal models [35]. The sequestering of bile acids can reduce
plasma glucose concentrations in diabetic mice [36] so the
potential use of bile acid-sequestering drugs in DM is
being investigated [37]. Changes in bile acids may also
impact on gut microflora-derived metabolites in this study
(for example, indolepyruvate and methylindolepyruvate),
as has been observed by Connor and colleagues [13].
Changes in other lipid species were also observed. Mul-
tiple fatty acids were observed to change, with seven
long-chain fatty acids present at higher concentrations in
diabetic rats. These changes indicate either an impair-
ment of adipose tissue storage of circulating fatty acids
and inhibition of hepatic fatty acid esterification or an
alteration to the uptake and utilization of fatty acids via
fatty acid beta-oxidation in mitochondria. Both arise
from insulin insensitivity causing increased concentra-
tions of non-esterified fatty acids in plasma and ulti-
mately increased beta-oxidation of fatty acids in liver and
skeletal muscle mitochondria producing short chain fatty
acids and ketone bodies. Increased ketone bodies were
observed in this study consistent with insulin deficiency
in diabetic animals. Free fatty acids have been shown to
cause insulin resistance in many tissues, including cardiac
and skeletal muscle [38].
Glycerophospholipids showed both increases and
decreases in their concentrations in diabetic rats in this
study, implicating changes in cellular membranes and lipo-
proteins in blood. Here, many lysoglycerophosphocholines
(lysoPCs) were decreased in diabetic rats, which indicate a
perturbation in the equilibrium between lysoPC produc-
tion (for example, via phospholipase A2 activity) and
lysoPC acetylation (for example, by acetyltransferase
enzymes). Although increases in lysoPC concentrations,
which are pro-inflammatory mediators, accompany
inflammatory responses in DM (for example, with islet
autoimmunity in T1D [3]), here we found that serum
levels of these pro-inflammatory mediators were
decreased. Similar decreases have been observed pre-
viously and were related to a shift from lysoPC degrada-
tion to glycerophosphocholine production [39].
Sphingolipids were also observed to change and may be
related to signaling and plasma membrane changes. Dys-
functional sphingolipid metabolism has been suggested to
contribute to metabolic stress in DM and to the pathogen-
esis of diabetic retinopathy [40,41]. In many of the lipid
changes observed there is no direct link between carbon
number or degree of saturation and whether these were
increased or decreased in STZ-induced diabetic animals.
Changes in the serum metabolome related to molecular
mechanisms of the response to TETA treatment
The second objective of this research was to identify meta-
bolites, classes of metabolites and/or metabolic pathways
that are perturbed in DM and return to a pre-diabetes
state following treatment with TETA. Some of the already
known mechanisms of action and effects of TETA (for a
review, see [42]) include: (i) increased urinary copper
excretion, (ii) decreased intestinal copper absorption,
(iii) telomerase inhibition, (iv) suppression of angiogenic
mediators (that is, vascular endothelial growth factor-1,
fibroblast growth factor-1, IL-1, IL-6, IL-8 and NFB),
(v) activation of the p38 mitogen-activated protein kinase
pathway, (vi) reduced over-expression of Cu/Zn superox-
ide dismutase, (vii) reversed activation of transforming
growth factor-beta and fibrosis in diabetes-induced
nephropathy, and (viii) suppressed carbonyl stress in
lenses of diabetic rats. However, TETA is likely to have
additional mechanisms of action and the objective was to
identify other TETA-related changes in the diabetic rats
by applying metabolomic technologies.
Multivariate PCA analysis showed no clear indication of
metabolic differences between STZ-induced diabetic/
TETA-treated and STZ-induced diabetic/untreated rats in
study 1 or study 2. Univariate analysis showed one meta-
bolic feature whose relative concentration change was
shown to be statistically significant in both study 1 and
study 2, putatively identified as hydroxybutanoate and/or
methyl-hydroxybutanoic acid. This change most likely
relates to the formation of ketone bodies, which is well
known in DM.
To further investigate any potential changes in the
serum metabolic profile of STZ-induced diabetic rats in
the presence or absence of treatment with TETA, pair-
wise correlation analysis was performed. Correlation
analysis was chosen to investigate the complex interac-
tion and regulatory mechanisms of biochemicals (meta-
bolites, proteins, mRNA and genes) in mammalian
systems. Metabolites are directly or indirectly correlated
to other metabolites in metabolic networks and other
direct or indirect correlations between metabolites and
other biochemicals are central to the regulation of biolo-
gical systems. Differences between pairwise correlations
were detected without statistically significant changes in
the concentrations of correlated metabolites. Therefore,
the investigation of these complex correlation networks
can provide further inferences about the effect of TETA
treatment.
Study 2 was chosen as the sample sizes for all four
groups were higher than for study 1 where two groups
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had only six rats at the end of the study because of
death of rats during the study. There were 6,514 245
and 1,965 153 pairwise comparisons in positive and
negative ion modes relating to 3,610 and 1,983 meta-
bolic features, respectively. Metabolic features were fil-
tered to provide only those features that show: (a) a
high positive or negative pairwise correlation for non-
diabetic/untreated rats; (b) a loss of this correlation or a
switch from a high positive correlation to/from a high
negative correlation for STZ-induced diabetic/untreated
rats (that is, a correlation coefficient change >0.5); and
(c) a return to a high positive or negative correlation in
the STZ-induced diabetic/TETA-treated rats. We found
that 30,784 and 4,040 metabolic features showed this
pattern in positive and negative ion modes, respectively.
To filter the data further, only metabolic features exhi-
biting this correlation pattern with ten or more different
metabolites were investigated further. This provided 857
and 77 metabolic features in positive and negative ion
modes, respectively, and related to 506 uniquely identi-
fied metabolites. These metabolites are listed in Addi-
tional file 1. Of specific interest are multiply charged
species, fatty acids and related metabolites, glyceropho-
spholipids, sphingolipids, vitamin D metabolites, sterol
metabolites and bile acids.
Specific classes of metabolites were observed as poten-
tially important in defining metabolic changes related to
TETA treatment of STZ-induced diabetic rats. Of the
unique metabolic features, 337 of 506 (66.7%) were defini-
tively assigned as multiple charged species (predominantly
doubly and triply charged species) by the isotopic pattern
observed for these metabolic features. Of these 337, 336
species were detected in positive ion mode. These species
could be peptides, doubly charged metabolites of TETA
(as TETA is a polyamine) or charged non-covalent asso-
ciations composed of metabolite and Cu (II) with a charge
state of +2 (defined as adduct ions). The charge state of
some metabolites detected in our study may be influenced
by the presence of metal ions (for example, Cu+ and Cu2
+). Further investigations of these metabolic features
showed that the mass difference between isotopic peaks
does not relate to expected mass differences that would be
observed for charged non-covalent associations composed
of metabolite and Cu (II) with a charge state of +2. The
mass differences observed did relate to expected mass iso-
topic differences between 12C and 13C for doubly and tri-
ply charged organic species. These are most probably
peptides in view of the hundreds of different features
detected (it would not be expected that there would be
hundreds of TETA metabolites present at high concentra-
tions), though the absence of TETA metabolites cannot
be proven without further targeted studies. It should
be noted that 28% of all detected metabolic features in
positive ion mode were allocated a multiply charged
assignment that is significantly greater than observed in
previous animal- or human-based studies in Manchester.
This is observed across all four groups and therefore is not
a direct result of disease or TETA treatment. However,
greater than 20 multiply-charged species were statistically
significant between non-diabetic/untreated and STZ-
induced diabetic/untreated rats. These results highlight
that the methods applied in this discovery study have
the potential to identify non-metabolic changes and
strengthen the applicability of the method. The changes in
the correlation network of peptides are most likely related
to changes in proteolysis (or protein catabolism) activity in
the diabetic state and then following TETA treatment.
Increased proteolysis in insulin resistance and DM has
been reported, most likely from the removal of the anti-
catabolic effect of insulin [43,44]. There is increased oxida-
tive stress in diabetes and this leads to tissue degeneration
and proteolysis. For example, oxidative stress in the retina
results in the activation of caspase-3 and apoptosis of
endothelial cells and pericytes [45], and inhibition of cas-
pase-1/IL-1beta signaling prevents degeneration of retinal
capillaries in DM [46]. Copper chelation will lead to
reduced oxidative stress and could prevent caspase
activation.
Reversible changes were observed in a number of lipid
classes and links between elevated cellular copper levels
and lipid metabolism have been reported [47]. These
include down-regulation of cholesterol and steroid bio-
synthesis pathways and fatty acid metabolism. In this
study, changes were observed in fatty acid metabolism
and sterol metabolism leading to cholesterol and bile
acid biosynthesis. Nineteen fatty acids and related meta-
bolites showed changes in this study and included pros-
taglandins, hydroxyl fatty acids and five fatty acid
amines or amides. These TETA-induced changes may
be due to decreased oxidative stress. Differences in fatty
acid amides may be linked to fatty acid amide hydrolase
(FAAH) as polymorphisms of FAAH genes have been
linked to obesity and insulin resistance [48] and endo-
cannabinoid system-related genes (of which FAAH is
one) have been shown to be effected by insulin dysregu-
lation in adipose tissue [49]. Thirty-seven glyceropho-
spholipids showed changes in this study. A wide range
of different glycerophospholipids showed changes, includ-
ing glycerophosphocholines, glycerophosphoethanola-
mines, glycerophosphoglycerols, glycerophosphoinositols,
glycerophosphoserines, phosphatidate and glyceropho-
sphocholine. These findings indicate a wide-ranging
change in glycerophospholipid metabolism related to
either cellular membranes or lipoproteins. It has been
shown that copper-induced oxidation of lipoproteins
affects structure [50] and fatty acid composition [51]. The
equilibrium between phospholipase activity and reacyla-
tion activity in DM was discussed in the previous section
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and the changes in several lysoPCs indicate a reversal to
higher lysoPC content following treatment. Six sphingoli-
pids show changes, including two sphingomyelins and
sphingosine-1-phosphate (S1P). Sphingolipids are impor-
tant bioactive molecules in signaling pathways involved in
apoptosis, proliferation, survival and angiogenesis. These
can also regulate oxidant activity. S1P plays an important
role in signaling in many disease, including DM [52], and
has been shown to regulate beta cell apoptosis [53].
Changes in S1P have been associated with diabetic compli-
cations [54], including in kidney nephropathy [55] and the
role of oxidative stress in diabetic skeletal muscle [56], and
has been shown as a potential biomarker of T1D [40].
These results show that even though clear changes in the
concentration of individual metabolites or peptides are not
observed in this study, the interactions between metabo-
lites or other biochemical species can be studied (and
changes observed) when studying correlation networks of
metabolites. This type of analysis provides evidence of
metabolism-related changes and changes in proteolysis as
a result of TETA-treatment.
Conclusions
STZ-induced diabetic rats have shown several metabolic
changes that have been previously observed and some
novel changes that require further investigation. The
STZ-induced diabetic rat is an appropriate model system
to investigate metabolic changes associated with DM and
observed in other animal models of DM, as well as
humans. The application of two independent biological
studies has highlighted the prevalence of false discovery
in these types of studies; many statistically significant
changes were observed in only one of two studies, sug-
gesting that they may be false positives. Finally, the meta-
bolic changes associated with TETA treatment have
shown that a range of biological mechanisms are impli-
cated and potentially resolved after TETA treatment in
diabetic rats, in particular including findings consistent
with suppression of proteolysis.
Materials and methods
All chemicals and reagents applied were of analytical
reagent grade or higher.
Animals and plasma collection
All animal experiments were conducted in accordance
with the UK Home Office regulations for the care and
use of laboratory animals, the UK Animals (Scientific
Procedures) Act (1986), and the ARVO Statement for
the Use of Animals in Ophthalmic and Vision Research.
Wistar adult male rats were included in the study and
were fed with standard laboratory chow and kept in a
12:12 h light:dark cycle. Two independent replicate stu-
dies were performed to reduce the probability of
reporting false positive observations. The replicate ani-
mal and metabolomic studies were separated in time.
Animal study 1 was performed from July to October
2009 and study 2 from February to April 2010. For each
study, the STZ-induced diabetic group (n = 20) con-
sisted of age-matched animals that received an intraperi-
toneal injection of STZ (55 mg/kg; Sigma Aldrich,
Gillingham, UK) and showed blood glucose levels of
≥30 mmol/L on two consecutive measurements 3 and
6 days after the injection. Assessment of the glycemic
state of the animals was carried out by measuring blood
glucose concentrations. This method can be easily
applied by collecting a small amount of venous blood
and is known to correlate well with serum levels of fruc-
tosamine and glycosylated haemoglobin. Given that only
a small blood sample is required, it alleviates the stress
associated with the serial blood sampling required for a
glucose tolerance test. Non-diabetic animals (n = 20)
were age matched and received an intraperitoneal injec-
tion of Na citrate buffer. Ten animals from each group
(STZ-induced diabetic and non-diabetic) were treated
with oral TETA (20 mg/kg/day; Sigma Aldrich) by
gavage from the day after STZ injection until the day
before they were sacrificed. Animals were housed in col-
lective cages (maximum of four per cage) and had free
access to water and food. Twelve weeks after STZ
administration, blood samples were collected from the
tail vein in non-fasting animals into 2 ml tubes (Greiner
Bio-One Ltd, Stonehouse, UK), placed on ice and subse-
quently centrifuged at 2,400g at 4°C. Serum was sepa-
rated into 200 μl sub-aliquots and stored at -80°C until
analysis. All blood samples were taken between 8:00 and
8:30 am for each individual animal included in each
study. The time between blood collection and storage
was less than 1 hour for all samples.
Metabolomics
Sample preparation
Samples were randomized before sample preparation.
Serum samples were thawed on ice, deproteinized and
the sample extract lyophilized in a similar approach as
previously described [57]. This process involved addition
of 240 μl of methanol to 80 μl of serum in a 2 ml Eppen-
dorf tube followed by vortex mixing (15 seconds) and
centrifugation (15 minutes, 13,685g). The supernatant
was transferred to a separate 2 ml Eppendorf tube and
was dried (HETO VR MAXI vacuum centrifuge attached
to a Thermo Svart RVT 4104 refrigerated vapor trap;
Thermo Life Sciences, Basingstoke, UK). Samples were
stored at 4°C until analysis. A pooled QC sample was
prepared by the pooling of 30 μl aliquots from each sam-
ple and vortex mixing (60 seconds). 80 μl aliquots of the
pooled QC sample were deproteinized and lyophilized as
described above. Samples collected in animal study 1 and
Ugarte et al. Genome Medicine 2012, 4:35
http://genomemedicine.com/content/4/4/35
Page 12 of 15
animal study 2 were prepared and analyzed in November
2009 and May 2010, respectively.
UPLC-MS analysis
Rat serum extracts and QC samples were analyzed
applying an Acquity UPLC system (Waters, Elstree, UK)
coupled to an electrospray hybrid LTQ-Orbitrap XL
mass spectrometer (ThermoFisher Scientific, Bremen,
Germany). All samples were analyzed separately in posi-
tive and negative ion modes. The UPLC and MS meth-
ods applied have been described previously [57]. QC
samples were analyzed for the first ten injections and
then every fifth injection. The final two injections were
also a QC sample.
Data processing and data analysis
Raw data files (.RAW) were converted to the NetCDF
format using the File converter program in XCalibur
(ThermoFisher Scientific). Deconvolution of the NetCDF
format files were performed using the XCMS software,
an open-source deconvolution program available for LC-
MS data as described previously [58] and each detected
metabolic feature was normalized to the QC sample
using quality control-robust loess signal correction (QC-
RLSC) [57]. Quality assurance (QA) was subsequently
performed and only metabolic features that were
detected in greater than 60% of all QC samples (from
injection 8) and with a relative standard deviation for
measured peak areas of <20% were retained for data ana-
lysis [57]. All other metabolic features were removed
from the dataset and ignored in subsequent data analysis.
All univariate and multivariate analyses were carried
out using the Matlab® scripting language [59] and
exploratory multivariate analysis was performed using
PCA. PCA was performed on data normalized to zero
mean and unit variance and the first three PCs were
investigated visually.
Univariate analysis was performed using the Mann-
Whitney U test, a non-parametric method for assessing
whether two independent samples of observations come
from the same distribution. No assumption is made of a
normal distribution and the test is identical to a one-way
analysis of variance (ANOVA) with the data replaced by
their ranks. For multivariate analysis all missing values
were annotated as 0 and in univariate analysis annotated
as ‘NaN’. All analyses were performed on data from both
ion modes separately but the results have been combined
post-data analysis to allow biological interpretation.
Pairwise correlation analysis
Pairwise metabolite correlations were calculated for data
acquired in study 2 separately for the four different
groups (STZ-induced diabetic/TETA-treated, STZ-
induced diabetic/untreated, non-diabetic/TETA-treated
and non-diabetic/untreated) using the non-parametric
Spearman rank correlation method and by applying the
bootstrapping method (n = 100). Final results only
included comparisons where there were a minimum of 6
versus 6 pair-wise peak correlations. All missing values
were annotated ‘NaN’. Changes in the correlation net-
work were then calculated by comparison of data from
(a) non-diabetic/untreated, (b) STZ-induced diabetic/
untreated and (c) STZ-induced diabetic/TETA-treated
groups. Metabolic features with a high correlation
(greater than +0.5 or less than -0.5) in non-diabetic/
untreated and STZ-induced diabetic/TETA-treated rats
but with a loss of the correlation coefficient (correlation
coefficient change >0.5) in STZ-induced diabetic/
untreated rats were retained as biologically important in
relation to TETA-treatment of STZ-induced DM. Only
metabolic features exhibiting this correlation pattern
with ten or more different metabolites were investigated
further.
Metabolite identification
Metabolic features, characterized by a unique accurate
mass and retention time, were putatively annotated
according to level 2 the Metabolomics Standards Initia-
tive guidelines [60] applying the PUTMEDID-LCMS
identification workflow operating in Taverna [61]. For
putatively annotated metabolic features, the accurate
mass for each peak was assigned a single or multiple
molecular formula matching in mass to the experimen-
tally determined mass with a mass error less than ±5
ppm. Features were subsequently matched to specific
metabolites by matching of the molecular formula to
metabolites present in the Manchester Metabolomics
Database [62]. Further filtering of data, based on
expected retention time ranges, was performed. It has
been shown that a single metabolite can be detected as
multiple metabolic features, each with the same reten-
tion time but different accurate mass [62]. Therefore,
data analysis can define multiple features of a single
metabolite as statistically significant. Also, isomers are
detected with the same accurate mass and retention
time, and therefore cannot be differentiated and all iso-
mers are reported.
Additional material
Additional file 1: File describing all uniquely identified metabolites
showing changes in pairwise correlation coefficients between non-
diabetic/untreated and STZ-induced diabetic/untreated rats and
changes in pairwise correlation coefficients between STZ-induced
diabetic/TETA-treated and STZ-induced diabetic/untreated rats.
Abbreviations
DM: diabetes mellitus; FAAH: fatty acid amide hydrolase; IL: interleukin;
lysoPC: lysoglycerophosphocholine; mTOR: mammalian target of rapamycin;
NF: nuclear factor; PCA: principal components analysis; QC: quality control;
S1P: sphingosine-1-phosphate; STZ: streptozotocin; T1D: type 1 diabetes;
T2D: type 2 diabetes; TETA: triethylenetetramine; UPLC-MS: ultra performance
liquid chromatography-mass spectrometry.
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